Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved zanubrutinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who are treatment naive and whose tumors have 17p deletion and/or TP53 mutated disease.
This is written in the approval document as:
As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), who are treatment naive and have del(17p) and/or TP53-mutated disease.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HSE (1) | TP53 somatic variants | Chronic Lymphocytic Leukemia | Zanubrutinib | |
| HSE (1) | TP53 deletion | Chronic Lymphocytic Leukemia | Zanubrutinib | |
| HSE (1) | 17p deletion | Chronic Lymphocytic Leukemia | Zanubrutinib |